Gilead Closes Ouro Deal; Lakefront Gets $500M War Chest as Nanobiotix Posts 57% NSCLC Response Rate
Gilead Sciences completed its acquisition of Ouro Medicines, handing Lakefront Biotherapeutics at least $500 million in deployable cash to build its inflammation pipeline. Nanobiotix's CONVERGE trial reported a 57.1% complete response rate in Stage 3 inoperable NSCLC—versus under 5% for standard of care—adding clinical momentum to biotech equities ahead of EHA 2026.
Salvado•